Department of Liver and Gastrointestinal Diseases, Biodonostia Health Research Institute - Donostia University Hospital, Ikerbasque, CIBERehd, Paseo del Dr. Begiristain s/n, E-20014, San Sebastian, Spain.
Department of Medico-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Viale dell'Università 37, 00185, Rome, Italy.
Nat Rev Gastroenterol Hepatol. 2016 May;13(5):261-80. doi: 10.1038/nrgastro.2016.51. Epub 2016 Apr 20.
Cholangiocarcinoma (CCA) is a heterogeneous group of malignancies with features of biliary tract differentiation. CCA is the second most common primary liver tumour and the incidence is increasing worldwide. CCA has high mortality owing to its aggressiveness, late diagnosis and refractory nature. In May 2015, the "European Network for the Study of Cholangiocarcinoma" (ENS-CCA: www.enscca.org or www.cholangiocarcinoma.eu) was created to promote and boost international research collaboration on the study of CCA at basic, translational and clinical level. In this Consensus Statement, we aim to provide valuable information on classifications, pathological features, risk factors, cells of origin, genetic and epigenetic modifications and current therapies available for this cancer. Moreover, future directions on basic and clinical investigations and plans for the ENS-CCA are highlighted.
胆管癌(CCA)是一组具有胆道分化特征的异质性恶性肿瘤。CCA 是第二大常见的原发性肝癌,其发病率在全球范围内呈上升趋势。由于 CCA 的侵袭性、晚期诊断和难治性,其死亡率很高。2015 年 5 月,“欧洲胆管癌研究网络”(ENS-CCA:www.enscca.org 或 www.cholangiocarcinoma.eu)成立,旨在促进和加强 CCA 在基础、转化和临床水平的国际研究合作。在本共识声明中,我们旨在提供有关该癌症的分类、病理特征、危险因素、起源细胞、遗传和表观遗传修饰以及现有治疗方法的有价值信息。此外,还强调了基础和临床研究的未来方向以及 ENS-CCA 的计划。